Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trialStéphane Palfi, Kyriacos Mitrophanous, Naoki Tani et al.|The Lancet|2014Cited by 436